Analyst Price Targets — PROF
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 7, 2026 1:42 pm | — | Lake Street | $12.00 | $7.95 | TheFly | Profound Medical price target raised to $12 from $11 at Lake Street |
| December 2, 2024 1:39 pm | Ben Haynor | Loop Capital Markets | $17.00 | $8.03 | StreetInsider | Profound Medical Corp. (PROF) PT Raised to $17 at Lake Street Capital Markets |
| July 23, 2024 8:41 am | Ben Haynor | Lake Street | $16.50 | $10.28 | TheFly | Profound Medical initiated with a Buy at Lake Street |
| July 15, 2024 5:02 pm | Rick Wise | Stifel Nicolaus | $12.00 | $9.15 | StreetInsider | Stifel Upgrades Profound Medical Corp. (PROF) to Buy |
Latest News for PROF
TORONTO, April 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company's business at the 2026 Bloom Burton & Co. Healthcare Investor Conference on…
LOS ANGELES, April 09, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Profound Medical Corp. , (“ Profound " or the "Company") ( NASDAQ : PROF ) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.
Cosmos Health (NASDAQ: COSM - Get Free Report) and Profound Medical (NASDAQ: PROF - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, risk and earnings. Earnings and Valuation This table compares Cosmos
TORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, is pleased to announce that the interventional MRI (“iMRI”) TULSA Procedure™ will be highlighted in several presentations at the 2026 Society of…
TORONTO, March 27, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, is pleased to announce that Texas Prostate, led by Dr. James Cochran, has achieved its 100th TULSA Procedure™ performed in Dallas Medical…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PROF.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.